MT-027

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameMT-027
Drug Alias NameMT-027
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derivedCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionAnti-CD276T lymphocyte replacements
TargetsCD276 antigen
Therapy Area/IndicationsCNS Embryonal TumorSolid tumoursPleural Effusion, Malignant +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesT-Maximum Pharmaceutical (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCancer Hospital Of Chinese Academy Of Medical SciencesT-MAXIMUM Pharmaceutical IncT-Maximum Pharmaceutical (Suzhou) Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsCNS Embryonal TumorSolid tumoursPleural Effusion, Malignant +[10] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A